China’s drug regulator, the National Medical Products Administration, has approved a new lung cancer therapy developed by Amgen. The announcement was made by its regional development and commercialization partner, BeOne Medicines, marking an important step in expanding access to innovative cancer treatments in China.
The therapy, known as tarlatamab, is designed for patients suffering from advanced small-cell lung cancer (SCLC), particularly those whose disease has progressed despite undergoing standard chemotherapy. This type of cancer is notoriously aggressive and difficult to treat, often leaving patients with limited options once first-line therapies fail. Tarlatamab represents a targeted immunotherapy approach, offering a more precise mechanism to combat cancer by harnessing the body’s own immune system.
In the United States, Amgen markets this drug under the brand name Imdeltra. It belongs to a class of treatments called bispecific antibodies, which are engineered to simultaneously bind to two different targets. In this case, the drug connects cancer cells with immune cells, effectively bringing them into close proximity so that the immune system can recognize and destroy the malignant cells. This innovative approach is part of Amgen’s broader pipeline of therapies aimed at improving outcomes for patients with challenging cancers.
Although the approval in China is a significant milestone, details regarding the drug’s launch timeline and pricing in the Chinese market have not yet been disclosed. Neither Amgen nor BeOne Medicines has provided further clarification on these aspects, leaving some uncertainty about how quickly patients in China will gain access to the treatment and at what cost.
Industry analysts are optimistic about the commercial potential of tarlatamab. Several Wall Street experts estimate that the drug could generate close to $2 billion in annual sales globally, reflecting strong demand for effective therapies in this area of unmet medical need.
The approval specifically covers the treatment of extensive-stage small-cell lung cancer (ES-SCLC), a form of the disease that has already spread widely within the body. While SCLC accounts for only about 15% of all lung cancer cases, it is generally more aggressive and has a poorer prognosis compared to non-small cell lung cancer. This makes advancements like tarlatamab particularly valuable for patients facing this diagnosis.
Before receiving full approval, Imdelltra underwent an accelerated review process by the U.S. Food and Drug Administration, which initially granted it conditional authorization more than two years ago. This was later converted into full approval approximately five months ago, reinforcing confidence in its safety and effectiveness. Additionally, the European Medicines Agency recently recommended the therapy for marketing authorization, further supporting its global adoption.
BeOne Secures China Approval for Imdelltra
China’s National Medical Products Administration has approved Imdelltra (tarlatamab), a bispecific T-cell engager developed by Amgen and commercialized in China with BeOne. The approval covers patients with extensive-stage small cell lung cancer (ES-SCLC), particularly those whose disease has progressed after chemotherapy.
This milestone represents a significant expansion for BeOne, enabling broader access to advanced immunotherapy in China.
BeOne and Amgen Bring Breakthrough Immunotherapy
Imdelltra works by targeting both cancer cells and immune T-cells, effectively redirecting the body’s immune system to attack tumors. This innovative approach underscores BeOne’s commitment to next-generation therapies.
Strategic Importance for BeOne in China
For BeOne, this approval is more than just a product launch—it reflects a strategic partnership model that accelerates access to global innovations. By collaborating with Amgen, BeOne strengthens its oncology portfolio and enhances its commercialization capabilities in China.
The approval also marks one of the first DLL3-targeting bispecific therapies available in the Chinese market, reinforcing BeOne’s leadership in cutting-edge cancer treatment.
BeOne Expands Access in a High-Need Market
Small cell lung cancer remains one of the most aggressive forms of cancer, with limited treatment options after relapse. Through this approval, BeOne is helping address a critical gap in care for patients who have exhausted standard therapies.
China’s large patient population and high incidence of lung cancer make this a significant commercial and clinical opportunity for BeOne.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
